More than 35,000 men in the United States die from prostate cancer each year. Now, a new study reveals the immune cell weaponry we might use to save lives. Researchers have discovered that the immune ...
LA JOLLA, CA — More than 35,000 men in the United States die from prostate cancer each year. Now, a new study reveals the immune cell weaponry we might use to save lives. Researchers have discovered ...
Background: Erectile dysfunction is a common late effect of prostate radiotherapy. Hydrogel spacers aim to reduce radiation exposure to nearby structures by increasing the distance between the ...
Early-onset prostate cancer: A time series analysis of age-stratified trends. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium. This abstract does not include a full ...
Researchers evaluated the impact of a plant-based diet on multiple QOL domains, including sexual function, in men with clinically localized prostate cancer. According to investigators, ‘The largest ...
ABSTRACT: Introduction: Androgen deprivation therapy is the standard treatment for metastatic prostate cancer. Its palliative action aims to improve patients’ quality of life through better control of ...
Prostate cancer is the most commonly diagnosed malignancy among men in Western countries and exhibits a remarkably heterogeneous clinical course, ranging from indolent tumors to rapidly progressive ...
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign prostatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results